Premium
Using Disease Progression Models as a Tool to Detect Drug Effect
Author(s) -
Mould D R,
Denman N G,
Duffull S
Publication year - 2007
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/sj.clpt.6100228
Subject(s) - clinical trial , medicine , clinical pharmacology , drug , intensive care medicine , null hypothesis , dosing , medical physics , disease , pharmacology , econometrics , economics
Generally, information required for approval of new drugs is dichotomous in that the drug is either efficacious and safe or not. Consequently, the purpose of most confirmatory clinical trials is to test the null hypothesis. The primary reasons for designing hypothesis testing trials are to provide the information required for approval using analyses techniques that are relatively straightforward and free of apparent assumptions. However, the information required for approval is very different from that used by prescribers for decision making. In the clinic, decisions must be made about dose adjustment for individual patients in the presence of additional therapies and co‐morbidities. Choice of drug and dosing regimen is therefore a classical risk to benefit decision that is often poorly informed from the results of confirmatory trials. Therefore, providing answers to the more difficult question of how to use the drug in a clinical setting is essential. Clinical Pharmacology & Therapeutics (2007) 82 , 81–86. doi: 10.1038/sj.clpt.6100228 ; published online 16 May 2007